TransCode Therapeutics Statistics
Share Statistics
TransCode Therapeutics has 833.62K
shares outstanding. The number of shares has increased by 0.78%
in one year.
| Shares Outstanding | 833.62K |
| Shares Change (YoY) | 0.78% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.09% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 400 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 116.33K, so 13.95% of the outstanding
shares have been sold short.
| Short Interest | 116.33K |
| Short % of Shares Out | 13.95% |
| Short % of Float | 13.95% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.4 and the forward
PE ratio is -0.78.
TransCode Therapeutics's PEG ratio is
0.01.
| PE Ratio | -1.4 |
| Forward PE | -0.78 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | -11.66 |
| P/FCF Ratio | -1.76 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for TransCode Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.56,
with a Debt / Equity ratio of -0.02.
| Current Ratio | 2.56 |
| Quick Ratio | 2.56 |
| Debt / Equity | -0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -584.07 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,393,567.29 |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -99.34% in the
last 52 weeks. The beta is 1.53, so TransCode Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.53 |
| 52-Week Price Change | -99.34% |
| 50-Day Moving Average | 251.01 |
| 200-Day Moving Average | 207.87 |
| Relative Strength Index (RSI) | 26.53 |
| Average Volume (20 Days) | 348,118 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.66M |
| Net Income | -16.75M |
| EBITDA | -16.19M |
| EBIT | -14.57M |
| Earnings Per Share (EPS) | -47.14 |
Full Income StatementBalance Sheet
The company has 5.81M in cash and 38.29K in
debt, giving a net cash position of 5.77M.
| Cash & Cash Equivalents | 5.81M |
| Total Debt | 38.29K |
| Net Cash | 5.77M |
| Retained Earnings | -63.2M |
| Total Assets | 13.19B |
| Working Capital | 10.53B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -13.34M
and capital expenditures -21.76K, giving a free cash flow of -13.36M.
| Operating Cash Flow | -13.34M |
| Capital Expenditures | -21.76K |
| Free Cash Flow | -13.36M |
| FCF Per Share | -37.51 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
